Who We Are
F-star is a clinical stage biotech developing next generation immunotherapies and working towards a future free from cancer and other serious diseases.
Learn More»Our Innovative Approach
F-star’s proprietary tetravalent bispecific antibody format is designed to ensure focused, potent and safe activation of the immune system.
Learn More»We are developing transformational cancer immunotherapies for patients who have few remaining options.
Our first-in-class and best-in-class drug candidates are designed to work with a patient’s immune system to stop tumors from evading the body’s defense mechanisms.
Our pioneering tetravalent or 2+2 bispecific antibody approach creates two new sites for antigen binding. We call this tetravalency. It’s an elegant solution on the natural human antibody format that does not disrupt its structure or functions.
We are focused on some of the most promising immuno-oncology targets in drug development, including LAG-3 and CD137, targeting a large and growing patient population with unmet medical need.
A stellar platform of novel tetravalent bispecific antibodies.
The strong dual-immune activation enabled by our tetravalent bispecific binding, we believe, will be more effective and enable a transformational shift in patient outcomes.
In development for over a decade, our innovative bispecific antibody platform is validated, patent protected and designed to safely reactivate the immune system to target hard-to-treat cancers.
